Smith & Nephew SNATS (SNN) Competitors $36.85 -0.18 (-0.49%) Closing price 09/19/2025 03:59 PM EasternExtended Trading$36.84 -0.01 (-0.01%) As of 09/19/2025 04:57 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsDividendFDA EventsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock SNN vs. GEHC, PHG, ZBH, SOLV, PEN, STVN, IRTC, BLCO, GKOS, and TMDXShould you be buying Smith & Nephew SNATS stock or one of its competitors? The main competitors of Smith & Nephew SNATS include GE HealthCare Technologies (GEHC), Koninklijke Philips (PHG), Zimmer Biomet (ZBH), Solventum (SOLV), Penumbra (PEN), Stevanato Group (STVN), iRhythm Technologies (IRTC), Bausch + Lomb (BLCO), Glaukos (GKOS), and TransMedics Group (TMDX). These companies are all part of the "medical equipment" industry. Smith & Nephew SNATS vs. Its Competitors GE HealthCare Technologies Koninklijke Philips Zimmer Biomet Solventum Penumbra Stevanato Group iRhythm Technologies Bausch + Lomb Glaukos TransMedics Group GE HealthCare Technologies (NASDAQ:GEHC) and Smith & Nephew SNATS (NYSE:SNN) are both large-cap medical companies, but which is the better investment? We will compare the two companies based on the strength of their analyst recommendations, valuation, profitability, media sentiment, dividends, earnings, institutional ownership and risk. Which has more risk and volatility, GEHC or SNN? GE HealthCare Technologies has a beta of 1.13, indicating that its share price is 13% more volatile than the S&P 500. Comparatively, Smith & Nephew SNATS has a beta of 0.71, indicating that its share price is 29% less volatile than the S&P 500. Do insiders and institutionals have more ownership in GEHC or SNN? 82.1% of GE HealthCare Technologies shares are owned by institutional investors. Comparatively, 25.6% of Smith & Nephew SNATS shares are owned by institutional investors. 0.3% of GE HealthCare Technologies shares are owned by insiders. Comparatively, 1.0% of Smith & Nephew SNATS shares are owned by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock is poised for long-term growth. Is GEHC or SNN a better dividend stock? GE HealthCare Technologies pays an annual dividend of $0.14 per share and has a dividend yield of 0.2%. Smith & Nephew SNATS pays an annual dividend of $0.89 per share and has a dividend yield of 2.4%. GE HealthCare Technologies pays out 2.9% of its earnings in the form of a dividend. Smith & Nephew SNATS pays out 41.2% of its earnings in the form of a dividend. Both companies have healthy payout ratios and should be able to cover their dividend payments with earnings for the next several years. GE HealthCare Technologies has increased its dividend for 1 consecutive years. Is GEHC or SNN more profitable? GE HealthCare Technologies has a net margin of 11.22% compared to Smith & Nephew SNATS's net margin of 0.00%. GE HealthCare Technologies' return on equity of 23.93% beat Smith & Nephew SNATS's return on equity.Company Net Margins Return on Equity Return on Assets GE HealthCare Technologies11.22% 23.93% 6.29% Smith & Nephew SNATS N/A N/A N/A Does the media favor GEHC or SNN? In the previous week, GE HealthCare Technologies had 17 more articles in the media than Smith & Nephew SNATS. MarketBeat recorded 19 mentions for GE HealthCare Technologies and 2 mentions for Smith & Nephew SNATS. GE HealthCare Technologies' average media sentiment score of 1.18 beat Smith & Nephew SNATS's score of 0.78 indicating that GE HealthCare Technologies is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment GE HealthCare Technologies 13 Very Positive mention(s) 0 Positive mention(s) 6 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Smith & Nephew SNATS 1 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Do analysts rate GEHC or SNN? GE HealthCare Technologies presently has a consensus price target of $88.40, suggesting a potential upside of 18.01%. Smith & Nephew SNATS has a consensus price target of $36.00, suggesting a potential downside of 2.31%. Given GE HealthCare Technologies' stronger consensus rating and higher probable upside, equities research analysts plainly believe GE HealthCare Technologies is more favorable than Smith & Nephew SNATS.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score GE HealthCare Technologies 0 Sell rating(s) 2 Hold rating(s) 8 Buy rating(s) 1 Strong Buy rating(s) 2.91Smith & Nephew SNATS 0 Sell rating(s) 6 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 2.00 Which has higher valuation & earnings, GEHC or SNN? GE HealthCare Technologies has higher revenue and earnings than Smith & Nephew SNATS. GE HealthCare Technologies is trading at a lower price-to-earnings ratio than Smith & Nephew SNATS, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioGE HealthCare Technologies$19.67B1.74$1.99B$4.8815.35Smith & Nephew SNATS$5.81B2.76$412M$2.1617.06 SummaryGE HealthCare Technologies beats Smith & Nephew SNATS on 16 of the 20 factors compared between the two stocks. Get Smith & Nephew SNATS News Delivered to You Automatically Sign up to receive the latest news and ratings for SNN and its competitors with MarketBeat's FREE daily newsletter. Subscribe Now View SMS TermsBy entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding SNN and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NYSE and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart SNN vs. The Competition Export to ExcelMetricSmith & Nephew SNATSMED PRODUCTS IndustryMedical SectorNYSE ExchangeMarket Cap$16.13B$10.82B$5.80B$21.60BDividend Yield2.41%1.88%5.63%3.52%P/E Ratio17.0621.2680.3529.95Price / Sales2.7632.26534.4760.41Price / Cash11.7324.5037.9924.97Price / Book3.063.4215.774.59Net Income$412M$210.63M$3.30B$1.00B7 Day Performance-2.44%-0.02%5.38%0.81%1 Month Performance-1.54%1.47%8.10%5.42%1 Year Performance20.54%-9.87%81.54%14.47% Smith & Nephew SNATS Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)SNNSmith & Nephew SNATS3.0076 of 5 stars$36.85-0.5%$36.00-2.3%+19.1%$16.13B$5.81B17.0617,349GEHCGE HealthCare Technologies4.2929 of 5 stars$77.76+1.7%$88.40+13.7%-17.3%$34.90B$19.67B15.9353,000Positive NewsAnalyst ForecastPHGKoninklijke Philips3.6744 of 5 stars$28.15-0.2%N/A-9.0%$27.15B$19.50B148.1666,678Short Interest ↓ZBHZimmer Biomet4.9092 of 5 stars$100.90-2.1%$111.00+10.0%-5.9%$20.42B$7.68B24.5517,000Trending NewsAnalyst ForecastSOLVSolventum2.1351 of 5 stars$73.19-0.3%$85.44+16.8%+2.0%$12.72B$8.25B33.8822,000PENPenumbra4.8301 of 5 stars$263.58-3.4%$302.93+14.9%+27.4%$10.64B$1.19B70.104,500Positive NewsSTVNStevanato Group1.8961 of 5 stars€26.21-0.8%N/A+35.2%€7.94B€1.19B48.545,521Positive NewsIRTCiRhythm Technologies1.1301 of 5 stars$176.16-2.0%$163.82-7.0%+139.5%$5.78B$657.23M-60.122,000Positive NewsBLCOBausch + Lomb2.0942 of 5 stars$15.23+0.2%$15.56+2.2%-24.0%$5.38B$4.79B-19.5213,500GKOSGlaukos4.6684 of 5 stars$80.72-2.5%$124.83+54.6%-35.9%$4.75B$383.48M-48.92780Positive NewsTMDXTransMedics Group2.4078 of 5 stars$114.29-0.2%$122.11+6.8%-26.3%$3.91B$441.54M59.22210Analyst Forecast Related Companies and Tools Related Companies GE HealthCare Technologies Competitors Koninklijke Philips Competitors Zimmer Biomet Competitors Solventum Competitors Penumbra Competitors Stevanato Group Competitors iRhythm Technologies Competitors Bausch + Lomb Competitors Glaukos Competitors TransMedics Group Competitors Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NYSE:SNN) was last updated on 9/20/2025 by MarketBeat.com Staff From Our PartnersREVEALED: Something Big Happening Behind White House Doorswhat I just learned about what’s unfolding in the White House is truly stunning… And you need to see it for...Paradigm Press | SponsoredCrypto Gets Official Government Backing—Here's the WinnerTrump Just Signed the GENIUS Act—One Coin is About to Explode We're at the BEGINNING of smart money really ...Crypto 101 Media | SponsoredMarket Panic: Trump Just Dropped a Bomb on Your Stockstock Market Panic: Trump Just Dropped a Bomb on Your Stocks The market is in freefall—and Trump's new tarif...American Alternative | SponsoredNvidia CEO Makes First Ever Tesla AnnouncementWhile headlines focus on Tesla’s car sales, tech analyst Jeff Brown says the real story is Tesla’s role in a $...Brownstone Research | SponsoredCollege grad makes $64,000 a monthA Wall Street legend just helped train our own proprietary AI system in the stock market (a project that took ...Stansberry Research | SponsoredWhat's the Best Way to Lower RMD Taxes?Turning 73 triggers a key IRS rule: you must begin taking required minimum distributions (RMDs) from certain r...SmartAsset | SponsoredHe Called Nvidia at $1.10. Now, He Says THIS Stock Will…The original Magnificent Seven returned 16,894%—turning $7K into $1.18 million. Now, the man who called Nvi...The Oxford Club | SponsoredAn $8 trillion-dollar discovery 17,000 ft underwater A strange rock pulled from the ocean floor may hold the key to a $16 trillion resource boom. Inside it: materi...Porter & Company | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Smith & Nephew SNATS, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Smith & Nephew SNATS With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
